3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
15
Breast Neoplasms
7
Sarcoma
5
Neoplasm Metastasis
4
Carcinoma, Ovarian Epithelial
4
Neoplasms
3
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multi-centric Castleman's Disease
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Osteosarcoma
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphadenopathy
1
Interventions
Bevacizumab
39
atezolizumab
26
durvalumab
24
Nivolumab
21
lenvatinib
20
tremelimumab
16
Specimen Handling
16
Magnetic Resonance Spectroscopy
13
sintilimab
11
pembrolizumab
11
Ipilimumab
10
tislelizumab
7
X-Rays
7
Sorafenib
7
Immunoglobulin G
7
regorafenib
6
Disulfides
6
Cyclophosphamide
6
cabozantinib
5
Radiotherapy
5
Radiosurgery
5
Blood Specimen Collection
5
Radiation
4
Oxaliplatin
4
Immunotherapy
4
Fluorouracil
4
Ethiodized Oil
4
Biopsy
4
fludarabine
3
donafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
liposomal doxorubicin
×
90 days
×
Clear all
No trials found.